A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs Doravirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 Status changed from not yet recruiting to recruiting as reported ClinicalTrial.gov record.
- 25 Mar 2014 New trial record